Latin America Pharmaceutical Products CMO Market is estimated to be valued at USD 25.5 Bn in 2026 and is expected to reach USD 38.46 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.95% from 2026 to 2033.
| Report Coverage |
Report Details |
| Base Year: |
2025 |
Market Size in 2026: |
USD 25.5 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: |
6.95% |
2033 Value Projection: |
USD 38.46 Bn |
Pharmaceutical products CMO provide wide range of manufacturing services, which include contract packaging, quality testing, and development service to pharmaceutical and biotechnology industries. Contract manufacturing organizations offer services from development of biologics to commercial scale production.
Market Dynamics
The Latin America pharmaceutical products CMO market is expected to witness significant growth during the forecast period, owing to the increasing expansion of international pharmaceutical companies in Latin America. For instance, in April 2020, the U.S. pharmaceutical company and French corporation Gennisium Pharma entered into the exclusive agreement under which m8 Pharmaceuticals has the exclusive rights to register and commercialize a more suitable formulation of an already existing orphan drug for apnea in Mexico and Brazil. Moreover, additional pipeline products for the treatment of conditions prevalent in premature newborn patients are also included in this partnership.
Low healthcare expenditure is expected to hinder growth of Latin America pharmaceutical products CMO market. For instance, according to the survey by Brazil's Federal Council of Medicine in 2018, per capita public spending on health care in Brazil did not increase above the country's official inflation, which rose by 80% from 2008 to 2017.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the Latin America pharmaceutical products CMO market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include BASF SE, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pisa Farmaceutica, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Inc., and Landsteiner Scientific
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The Latin America pharmaceutical products CMO market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Latin America pharmaceutical products CMO market
Market Segmentation
- By Service Type (Revenue, USD Bn, 2021-2033)
- Contract Manufacturing Services (CMO)
- Active Pharmaceutical Ingredient (API) Manufacturing
- Small Molecule APIs
- Biologic APIs
- Finished Dosage Form (FDF) Manufacturing
- Solid Dosage Forms
- Injectable Dosage Forms
- Semi-solid Dosage Forms
- Liquid Dosage Forms
- Primary Packaging
- Secondary Packaging
- Contract Research Services (CRO)
- Target Identification
- Lead Optimization
- In Vitro Studies
- In Vivo Studies
- Phase I
- Phase II
- Phase III
- Phase IV
- Regulatory Affairs Services
- Pharmacovigilance Services
- Medical Writing Services
- By Product Type (Revenue, USD Bn, 2021-2033)
- Small Molecule Drugs
- Biologics
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Cell & Gene Therapies
- Biosimilars
- By Therapeutic Area
- Oncology
- Infectious Diseases
- Cardiovascular Diseases
- Neurology
- Metabolic Disorders
- Respiratory Diseases
- Immunology
- Rare Diseases
- Others
- By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Generic Drug Manufacturers
- Academic & Research Institutes
- Government Organizations
- By Region (Revenue, USD Bn, 2021-2033)
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Key Players
- BASF SE
- Bayer AG
- Boehringer Ingelheim GmbH
- Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Pisa Farmaceutica
- Fresenius SE & Co. KGaA
- Takeda Pharmaceutical Company Limited
- Ferring Pharmaceuticals, Inc.
- Landsteiner Scientific